News | Cardiac Imaging | November 13, 2024

New X-ray Imaging Technique Helps Early Identification of Heart Disease Risk

A recent study has demonstrated the value of the single-exposure dual-energy X-ray detector in advancing cardiovascular risk assessment.


Nov. 13, 2024 – A recent study has demonstrated the value of the single-exposure dual-energy X-ray detector in advancing cardiovascular risk assessment.

Published in the Canadian Association of Radiologists Journal, the paper, Opportunistic Identification of Coronary Artery Calcium and Valve/Vascular Calcifications on Chest X-ray: Improvement with Single-Exposure Dual-Energy Imaging,” establishes the potential of single-exposure dual-energy imaging in detecting coronary artery calcifications (CAC).

With improved accuracy over conventional X-rays, the dual-energy X-ray technology has the ability to highlight soft tissues in addition to bone, leading to improved detection in different structures of the body. CAC detection is crucial for assessing cardiovascular risk, as CAC presence strongly correlates with coronary artery disease and related complications.

Conducted at University Health Network, Dr. Patrik Rogalla’s research indicates that single exposure dual-energy imaging detects more CAC compared to traditional X-ray methods. This represents a possible promising, cost-effective option for early intervention in cardiovascular risk management.

Traditional X-ray detectors use one exposure to radiation to create one image, a digital radiograph. KA Imaging’s Reveal 35C, however, uses the same single X-ray exposure at the same dose to create three distinct images, a regular DR image, a soft tissue image, and a bone image. This patented technology is called SpectralDR. Its optimized radiation use also allows for lateral imaging, making it easier to see behind the heart.

In this study, researchers observed 61 bone marrow transplant patients selected for their higher cardiac complication risk. Each patient received both a dual-energy chest X-ray and a low-dose chest CT, considered to be the reference standard for CAC detection, for comparison. Two experienced radiologists independently assessed the images. Results showed that dual-energy imaging detected CAC with higher diagnostic confidence than the traditional X-ray.

According to the study authors, “The single-exposure, dual-energy chest X-ray has shown improved detection of both calcium deposits in the heart’s arteries, as well as valve and vascular calcifications – both indicators of a higher risk for heart disease  –  when compared to conventional X-ray imaging.”  They suggest that “the initial X-ray finding may help clinicians with assessing risk earlier, and guide additional testing if clinically warranted, all leading to improved risk management for patients at risk of heart disease and/or a cardiac event.”

For more information, please visit www.kaimaging.com.


Related Content

News | Cardiovascular Clinical Studies

May 6, 2026 — Image Analysis Group (IAG), a global imaging CRO headquartered in London, U.K., and HeartcoR Solutions ...

Home May 06, 2026
Home
News | Cardiovascular Clinical Studies

April 9, 2026 — Mount Sinai researchers have created an analytic tool using machine learning that can predict ...

Home April 14, 2026
Home
News | Cardiovascular Clinical Studies

April 13, 2026 —The American Heart Association (AHA) has granted Case Western Reserve University the Rapid Impact ...

Home April 13, 2026
Home
News | Cardiovascular Clinical Studies

April 2, 2026 — Iterative Health and US Heart & Vascular (USHV) have announced a strategic partnership to advance ...

Home April 02, 2026
Home
News | Cardiovascular Clinical Studies

March 4, 2026 — UltraSight, a provider of AI-guided cardiac imaging workflows, has announced Late-Breaking clinical ...

Home March 04, 2026
Home
News | Cardiovascular Clinical Studies

Feb. 9, 2026 — HTA and MedAxiom have opened applications for the 2026 HeartX program, a cardiovascular-focused ...

Home February 18, 2026
Home
News | Cardiovascular Clinical Studies

Jan. 5, 2026 — Medera Inc., a clinical-stage biopharmaceutical company focused on targeting cardiovascular diseases by ...

Home January 05, 2026
Home
News | Cardiovascular Clinical Studies

Nov. 10, 2025 —Genomics, a science-led techbio company, has today announced new research that suggests polygenic risk ...

Home November 12, 2025
Home
News | Cardiovascular Clinical Studies

Oct. 21, 2025 – AskBio Inc., a gene therapy company wholly owned and independently operated as a subsidiary of Bayer AG ...

Home October 21, 2025
Home
News | Cardiovascular Clinical Studies

Aug. 25, 2025 — Merck, known as MSD outside of the United States and Canada, has announced that new clinical trial and ...

Home August 25, 2025
Home
Subscribe Now